News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping
Local Bloggers Cheap Tech Eco-Confessions Faceoff Furst Draft Heard on the Street Med City Movie Guy Pulse on Health Political Party

Search PB Blogs

Loading

Categories

872 posts categorized "Mayo Clinic"

September 01, 2015

Celyad, Medisun collaborating on new China deal

Two international firms with deep Mayo Clinic and Rochester ties are joining forces for a new $22.4 million collaboration. 

Belgium-based Celyad, formerly called Cardio3, announced Monday it's entering into a new venture and distribution deal with its partner, Medisun International Limited, for its C-Cure cardiac treatment. C-Cure is based on stem-cell technology called cardiopoiesis licensed from Mayo Clinic.

CelyadBoth Celyad and the Hong Kong-based Medisun continue to collaborate with Mayo Clinic and both are in the process of creating facilities in Rochester.

This new 15-year agreement between Celyad and Medisun guarantees Celyad will "conduct all clinical development and undertake any regulatory steps necessary for market approval in China, Hong-Kong, Taiwan and Macau (collectively 'Greater China')," according to a news release about the venture.

Medisun will fund that push with a minimum of 20 million Euros, or $22.4 million. In addition to the funding cash, Celyad will collect royalties and profit sharing. The royalty rates, based on the total revenues from C-Cure, are expected to range from 10 percent to 30 percent. Profit-sharing amounts will be based on total revenues after royalties are taken out. The profit sharing is expected to range from 20 to 25 percent.

"We are pleased to have this new license agreement in place with our local partner Medisun, which give us full control over clinical developments in these territories, fully funded by our local partner. Pending receipt of necessary approvals, we look forward to giving access to this technology to patients in Greater China," stated Celyad CEO Christian Homsy in the release.

6a00d83451cc8269e201b8d0c98293970c-120wiCelyad is paying rent on the entire fifth floor, or 14,963 square feet, in the city of Rochester's Minnesota Biobusiness Center. The city signed a lease with Celyad earlier this year for it to develop a prototype manufacturing facility in the downtown building. Construction has been underway for months, but is not yet completed. The five-year lease calls for Celyad to pay a rent of $18 per square foot, or $22,444.50 per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

Local officials hope to convince Celyad to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to officials at Rochester Area Economic Development Inc.  Celyad also has plans to build a U.S. headquarters in Boston.

The company recently reported a $17.04 million loss for the first half of 2015. It lost $18.1 million for the whole year in 2014, up from $15.9 million in losses in 2013. Dr. Homsy told Reuters last week the company has enough cash to make it through the end of 2017.

The company did an initial public stock offering in 2014, which yielded about $500,000 worth of shares for Mayo Clinic.

Medisun also is collaborating with Mayo Clinic on a project to bring more patients from China to Rochester for treatment. While Medisun began building a $1 million office in the H3 Plaza building in downtown Rochester earlier this year, it recently put an end to that project.

Mayo Clinic, however, has confirmed it still is working with Medisun. Mayo Clinic spokeswoman Duska Anastasijevic said she didn't believe "the scope and nature of the relationship has been impacted or altered, just the planned location of their offices has changed." 

She added that Mayo staff working with Medisun said the company will be using one of its Rochester homes as "a guest house" and headquarters for the project. Medisun CEO Danny Wong personally owns two houses in Rochester. He bought a house at 2515 Crest Lane SW for $1.4 million as well as one at 615 10th Ave. SW for $1.31 million. It is not known which property will serve as the guest house.

August 19, 2015

Mayo Clinic officially opens Mayo Medical Labs expansion

About a year after breaking ground on the project, Mayo Clinic officially opened a 60,000-square-foot expansion of its Superior Drive Support Center on Tuesday.

The Superior Drive Support Center, which houses Mayo Medical Laboratories, is located at 3050 Superior Drive NW. The three-story addition built on the south side of the complex. Mayo Clinic is moving its the toxicology, endocrinology and proteomic core labs to the new space from downtown. They expect to be fully moved in by April.

Moving those three labs out of the Hilton Building will open up 24,000-square-feet of space. While this expansion will not bring new jobs, it will mean moving 150 to 170 people out of downtown to join the more than 1,000 Mayo Medical Labs employees at the Superior Drive complex.

"That's essential to allow other Mayo labs to decompress," said Dr. Matt Binnicker, the chair of the Department of Laboratory Medicine and Pathology's Facilities and Space Committee, in 2014. "Having those labs here makes a lot of sense."


Mayo Medical Labs, which generates revenue for Mayo Clinic, performs about 20 million tests for more than 4,000 hospitals annually.

Binnicker explained that while the three labs handle tests for both Mayo Clinic's patients and Mayo Medical Labs clinical customers, about 90 to 95 percent of their work is for MML.

Mayo Clinic moved into the 13-year-old complex in 2004. By 2011, about 800 employees worked at the facility. It originally was built by electronics manufacturer Celestica Inc. in 2001. When that company closed its Rochester operation, the building was left empty.

Mayo Clinic leased the property for eight years, until it paid $18.5 million in August 2012 to buy it. Before that, it was owned by 17 national investors through Triple Net Properties of Santa Ana, Calif., until they defaulted on the mortgage in 2012. The investors bought the property for $36.8 million in 2006.

When the mortgage defaulted, HSBC Bank USA took over the property. HSCB then sold it to Mayo Clinic.

While it originally was under construction, New York City-based W. P. Carey & Co. LLC bought the complex from Celestica, which leased it back. W.P. Carey later sold it for about 70 percent more than the $21.6 million it paid.

August 10, 2015

TapImmune using Mayo Clinic tech for possible cancer vaccine

 

Assistant Manager Editor Mike Klein spotlighted a press announcement from a Seattle-based biotech company called TapImmune Inc. working with Mayo Clinic this morning.

I remember in 2010, when TapImmune first licensed Mayo Clinic technology and began collaborating with Mayo's world-renowned vaccine exTapimmunelogopert, Dr. Gregory Poland.

At that point, they were working with a Small Pox construct to create the vaccine for cancer as well as other infectious threats like, Ebola.

In May of this year, reports came out about Mayo Clinic's Dr. Edith Perez saying how this vaccine changed her view towards preventative medicine. She is working with TapImmune oon applying the vaccine to fight breast cancer.

TapImmune had only $142,000 in and $3.3 million in losses at that point in May.

This appears to be a promising company with deep ties to Mayo Clinic. It seems like a good candidate to based in Rochester rather than someplace like Seattle.

Here's some of what Klein filed on this for today's paper:

Seattle-based TapImmune Inc. has exercised its option agreement with Mayo Clinic to use its technology in a possible vaccine for certain types of cancer, it announced.

TapImmune signed a worldwide exclusive license agreement to commercialize a "proprietary folate receptor alpha vaccine technology for all cancer indications."

This technology, developed in the laboratory of Keith Knutson at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer. The trial demonstrated the experimental therapy was "safe, well-tolerated, provided a robust immune response," according to the news release. Next, TapImmune plans a Phase II clinical trial in the second half of the year.

TapImmune CEO Dr. Glynn Wilson said the company's future clinical programs will be "aimed at developing this leading vaccine candidate as a stand-alone therapy or in combination with other immunotherapies."

Mayo Clinic has a financial interest in the technology.

August 05, 2015

Insurer expands relationship with Mayo Clinic to bring more patients here

Two Minnesota health-care giants, Mayo Clinic and UnitedHealth Group, are joining forces to bring thousands of new patients to Rochester and other Mayo sites for treatment.

The Eden Prairie-based insurance provider UnitedHealth announced today it will recommend that patients with certain conditions travel to Mayo Clinic for care, through UnitedHealth's Optum Centers of Excellence Program.

800px-Gonda_building,_closer_upCompanies can sign up for coverage under the Centers of Excellence through UnitedHealth or directly through Optum. That means referring patients to designated sites, such as Mayo Clinic's campuses in Rochester, Florida and Arizona, for treatment. Participating in the program may include some coverage of travel and lodging costs.

Mayo Clinic has been listed by Optum as a Center for Excellence for organ transplants for 11 years. Optum says it makes more than 14,000 transplant referrals a year. Neither group said how many Optum organ transplant referrals come to Mayo Clinic each year.

Today's announcement adds the three Mayo Clinic locations to the list of preferred sites for treatment of cancer, heart failure, congenital heart disease, infertility and bariatric surgery.

“This expanded relationship with Mayo Clinic provides patients in participating health plans from around the country with greater access to clinically superior, cost-effective health care,” stated Mike Weissel of Optum Consumer Solutions in today's announcement.

Neither Mayo Clinic nor UnitedHealth released any estimates on how many more patients this might bring to Mayo Clinic or how much money it might bring in for Mayo Clinic. However, it clearly could be a great boon for the medical center and communities such as Rochester.

All of the new conditions added to list are major medical treatments. A look at just bariatric surgery shows the potential for growth. 

Mayo Clinic reports it performs more than 300 bariatric surgeries a year in Rochester. The American Society for Metabolic and Bariatric Surgery estimated a total of 179,000 bariatric surgeries were performed in the U.S. in 2013.

Both Mayo and Optum stressed how this new relationship will benefit patients by providing "access to high-quality, cost-effective care."

“Health plans and employers know the value of sending patients with complex and or rare conditions to high-quality centers such as Mayo Clinic,” said Dr. Charles Rosen, Mayo Clinic's medical director of contracting and payer relations.

Today's announcement marks the latest collaboration between Mayo Clinic and UnitedHealth/ Optum. Earlier this year, Mayo Clinic announced its partnership with Optum360 for revenue management services.

In 2013, they launched "a strategic research alliance"  to create a state-of-the-art facility in Cambridge, Mass under the umbrella of OptumLabs. OptumLabs is a for-profit unit of UnitedHealthcare's Optum division, which earned $1.3 billion in 2011. 

The research facility today has 22 major corporate partners and has more than 100 studies in process.

Boston Scientific buys major stake in local firm, Preventice

Preventice Solutions, a maker of wearable cardiac monitors with deep Rochester roots, is getting a major boost from a medical giant.

Boston Scientific Corp. announced Tuesday it now is "a significant shareholder" in Preventice as well as its "exclusive worldwide sales and marketing representative."

Preventice, which has a large development center in northwest Rochester, makes the wearable BodyGuardian Remote Monitoring System, developed from research licensed from Mayo.

144536The new deal clears the way for Preventice to reach the remote monitoring market estimated to total $19 billion to $21 billion by 2016. Experts anticipate almost five million patients will be using some type of wireless monitoring by then.

"As our health-care environment continues to evolve, health-care practitioners, administrators and payors are looking for solutions that identify relevant clinical insights from large volumes of patient data and integrate those insights to improve clinical decision-making," said Boston Science Executive Vice President Joe Fitzgerald in Tuesday's announcement.

Fitzgerald described Preventice as having "an infrastructure optimized to monitor hundreds of thousands of patients each year."

The privately owned firm has grown quickly since being launched in 2007 with only its founders on staff. Preventice evolved from Boost Information Services. It was founded by Jon Otterstatter, Greg Wobig, Dan Spors and Scott Burrichter.

Preventice started as a developer of medical information smartphone apps, in collaboration with Mayo Clinic and Merck. Then it shifted gears to begin developing wearable cardiac monitors. The U.S. Food and Drug Administration approved its wireless BodyGuardian monitor to be prescribed to track nonlethal arrhythmia, or irregular heartbeats, in 2012.

In 2013, Preventice began shipping out its BodyGuardian systems to feed what CEO Otterstatter described then as the health-care industry's growing "fever" for remote medical monitoring. That year, it expanded to about 100 employees, with about half in Preventice's Rochester offices. Based in Minneapolis, Preventice also has an office in Fargo, N.D.

Preventice Solutions merged with Houston, Texas-based eCardio Diagnostics in 2014, under the holding company of Preventice Inc.

July 23, 2015

Quiet period to end for Celyad (former Cardio3) on July 29

Here's an interesting update from a site called Marketbeat.com about the former Cardio3, now trading in U.S. as Celyad. This Belgium firm has deep ties to Mayo Clinic and will soon occupy an entire floor of the Minnesota Biobusiness Center in downtown Rochester.

 Celyad SA’s  quiet period is set to expire on Wednesday, July 29th. Celyad SA had issued 1,460,000 shares in its initial public offering on June 19th, Market Beat reports.

CelyadThe total size of the offering was $100,097,600 based on an initial share price of $68.56. During Celyad SA’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

 

CYAD has been the subject of a number of recent recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Celyad SA in a research note on Tuesday, July 14th. They set an “overweight” rating and a $95.00 price target on the stock. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Celyad SA in a research note on Sunday, June 21st.

Celyad SA remained flat at $60.44 during during mid-day trading trading on Wednesday. 126 shares of the company’s stock traded hands. Celyad SA has a one year low of $47.52 and a one year high of $67.94. The stock’s 50-day moving average is $54.65 and its 200-day moving average is $54.65.

 

July 14, 2015

Piper Jaffrey gives Celyad (former Cardio3) stock positive rating

Here's an interesting item that floated into my email box this a.m. about the former Cardio3, now trading in U.S. as Celyad. This Belgium firm has deep ties to Mayo Clinic and will soon occupy an entire floor of the Minnesota Biobusiness Center in downtown Rochester.

By the way, a rating of "overweight" is a good thing. It means the stock is a better value that other stocks in the same sector.

Here's the item as posted by Piper Jaffray:

Piper Jaffray initiates coverage on Celyad SA with a Overweight rating and a price target of $95.00.

Analyst Edward Tenthoff commented, "Celyad is a leading cell therapy company. CelyadCelyad is conducting the Phase III CHART-1 trial of autologous cell therapy C-CURE in heart failure patients with data likely next summer. The company will initiate the CHART-2 trial this year with data in 2017. Celyad recently in-licensed novel CAR-T technology for cancer currently in a Phase I AML and multiple myeloma study. Celyad is listed on the EuroNext exchange in Brussels and Paris, and just completed a U.S. IPO issuing 1.46 million shares at US$68.56 raising gross proceed of US$101 million. CYAD shares have sold off since the IPO providing an attractive entry point at US$54.71, in our view. We are initiating coverage with an Overweight rating and US$95 price target."

Shares of Celyad SA closed at $54.71 yesterday.

 

 

June 15, 2015

Former Cardio3 launching $99 million IPO in US and worldwide

Celyad, formerly Cardio3 Biosciences, announced the terms for its $99 million stock offering this morning.

The Belgium-based Celyad, which is building a manufacturing facility in downtown Rochester and has close ties with Mayo Clinic, hopes to raise $99 million by offering 1.4 million shares at $70.98 per share.

CelyadWhile Celyad has traded on the European stock markets of NYSE Euronext Brussels and NYSE Euronext Paris for some time, this stock offering would introduce the regenerative medicine firm directly to the U.S. market. It has applied to make the U.S. offering on the Nasdaq stock market under the symbol CYAD.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. It cannot sell or accept offers to buy until the SEC OKs the registration.

This move could benefit Mayo Clinic, which owned 2.69 percent of Celyad as of March 3. Mayo Clinic first acquired equity in Cardio3 in 2007, when it licensed stem-cell research by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. Its cardiopoiesis technology repairs patients' hearts by re-programming their own stem cells to regenerate cardiac tissue.

Earlier this year, the Rochester City Council recently approved a lease for Celyad to take over the entire fifth floor of Rochester's Minnesota BioBusiness Center. Rochester Area Economic Development Inc. and the Minnesota Department of Employment and Economic Development also are involved in the deal.

Celyad is building a prototype manufacturing facility in the 14,963-square-feet of space on the fifth floor of the downtown building. Mayo, which leases the fourth through eighth floors, moved its employees out of the fifth floor earlier this year. The five-year lease calls for it to pay a rent of $18 per square foot, or $22,444.50, per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

DEED is offering Ceylad a $357,000 Minnesota Job Creation Fund award if it invests $1.5 million in Rochester within a year and hires 33 employees within two years. The average wages of the new jobs will be $21.52 per hour.

May 28, 2015

Mayo hires consultant to map out Discovery Square

To help fire up Discovery Square as "a catalyst" to create jobs in downtown Rochester, Mayo Clinic has contracted a feasibility study, independent of the Destination Medical Center Corp.

Mayo Clinic has hired the DMC development manager, Hammes Co. of Madison, Wis., to analyze the Discovery Square piece of the DMC vision and offer a market plan of how DiscoverySquarethe medical and technology research area might be developed. Mayo is paying Hammes $1.5 million to conduct the study, which is expected to be completed by the end of the year.

One expected tenant is Epic, a Madison-based software system that recently signed a contract to help build an electronic health record system for Mayo Clinic. It's planning on having many employees based in Rochester.

"They've indicated a strong interest in the Discovery Square concept, and we're exploring ways they may participate in that," said Bolton.

Discovery Square is described as "the focal point" for Mayo Clinic's expansion of its science and technology institutes, and it's designed as a place for private companies and others to work with Mayo on research and other projects. It's marked on the DMC map as being central to the Gonda Building and the Mayo Medical School.

"The Square is designed to be playful and artful, similar to the Google Commons in order to, quite simply, attract the best and the brightest, the most creative minds in the world," according to the DMC plan.

Mayo Clinic owns about 35 percent of the property within the proposed Discovery Square area.

The goal of the new study is to map out the area more specifically and identify potential partners and funding streams to make it sustainable.

Jeff Bolton, Mayo's chief administrative officer and the chair of DMC's Economic Development Agency, said Mayo funded the study because it's not part of the DMC EDA's scope.

"The EDA budget is really to provide staffing to support the DMCC board, to work with developers and help market the DMC concept," he said. "Mayo Clinic views this as area where we could serve as an important catalyst to advance the DMC vision. That's why we stepped up and are making this investment."

Mayo Clinic's relationship with Hammes dates back to the very early days of the DMC concept in 2008 before it became public. Mayo Clinic first officially contracted with the company about DMC in 2011. When the EDA signed its own contract with Hammes last year for $2.3 million a year, it had no ongoing Mayo contracts.

Bob Dunn, president of Hammes, explained that this study will be similar to his company's work on the overall DMC plan but will be much more detailed.

This study will include a master plan, a conceptual design, preliminary engineering, financial analysis, financing plan, a market analysis, a review of effective land use and operational aspects for Discovery Square.

"This will be a block-by-block plan," he said. "But we're not starting at ground zero. Mayo, which owns a good portion of the land in Discovery Square, has already thought a lot about this development."

Meanwhile, Mayo is actively working with companies to try to get them to locate there, Bolton said.

"We're out marketing the concept," said Mayo's Bolton. "Obviously, we have an interest in terms of attracting groups to collaborate with us."

The project's success likely will be driven by what partners want to work with Mayo Clinic.

"If I were to forecast, I'd say there will be multiple of owners of facilities in Discovery Square. Many will probably be owned by private developers," predicted Bolton. "There won't be a monolithic owner of the facilities. The free market will play out in this environment."

He added that Mayo Clinic may participate "directly or indirectly" in some of the development.

The multimillion dollar question is when actual development of this new job generator area will begin.

"We'll need a critical mass of corporate engagement in order to have a developer to put that first shovel in the ground," said Bolton.

Dunn said this is a fascinating feature of what is already a unique project.

"DMC and Discovery Square, to me, is one of the most interesting things that I can think of nationally in terms of major economic development," he said. "It's unique because impact Mayo Clinic can bring to something like this in a market that's now beginning to mature and evolve very quickly."

May 05, 2015

Tech security chief leaves Mayo Clinic for new job

Mayo Clinic's chief information security officer is leaving Rochester to join a Colorado technology firm.

3a01a19James Carder made the announcement on Twitter Tuesday saying, "It's with mixed emotions to announce that I have officially left Mayo Clinic and taken a new role as CISO (chief information security officer) @LogRhythm & VP of @LogRhythmLabs."

Carder was Mayo's technology security chief from June 2013 until this week. Described as "a frequent speaker at industry events and noted author of several security publications," Carder managed the security of the 250,000 to 300,000 devices connected to Mayo Clinic's network, according to the Wall Street Journal.

While at Mayo Clinic, the Wall Street Journal said he also created "an incident response infrastructure" and as well as Mayo Clinic’s first cyber threat intelligence organization.

At LogRhythm, Carder will serve as the chief information security officer and vice president of LogRhythm Labs. The Boulder, Colo.-based firm stated in the announcement of the hiring that Carder will set "the vision for and direct the company’s global information security program." He will manage 12 employees.

Carder told the Wall Street Journal that his primary reason for the move is "speed."

“The main difference is that things you do have a ripple effect quickly,” he explained to the WSJ.